Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2034

Name: Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2034
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Download Sample Buy Report

Induced Pluripotent Stem Cell (iPSC) Market 2025 - By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cell Types), By Application (Academic Research, Drug Discovery And Toxicity Studies, Regenerative Medicine, Cell And Gene Therapy), By End-User (Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users) - Market Size, Trends, And Global Forecast 2025-2034

Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2034

Report Price : $4490.00 | Pages : 346 | Published : July 2025 | Delivery Time: Immediately | Format :

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Regional Data

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Induced Pluripotent Stem Cell (iPSC) Market Definition

Induced pluripotent stem cells (iPSC), are a type of artificial stem cells that are pluripotent, which can give rise to several different cell types, but are produced directly from somatic cells.

The induced pluripotent stem cell (IPSC) market consists of the sales of induced pluripotent stem cell (IPSC) by entities (organizations, sole traders, and partnerships) that are derived from adult somatic cells such as fibroblasts or blood cells that have been reprogrammed into pluripotent stem cells by the introduction of a set of transcription factors linked to pluripotency. The resulting iPSCs can then be differentiated into a variety of cell types, such as cardiomyocytes, neuronal cells, hepatocytes and hematopoietic cells, using in vitro differentiation protocols.

Induced_Pluripotent_Stem_Cell_iPSC_Global_Market_Opportunities_And_Strategies_To_2034_Market_2025_Graph

Induced Pluripotent Stem Cell (iPSC) Market Size

The global induced pluripotent stem cell (iPSC) market reached a value of nearly $1,961.76 million in 2024, having grown at a compound annual growth rate (CAGR) of 10.74% since 2019. The market is expected to grow from $1,961.76 million in 2024 to $3,099.47 million in 2029 at a rate of 9.58%. The market is then expected to grow at a CAGR of 8.87% from 2029 and reach $4,739.53 million in 2034.

Growth in the historic period resulted from increasing healthcare expenditure, increase in the prevalence of chronic disorders, growing interest in personalized medicine, increasing prevalence of neurological disorders and rising prevalence of genetic disorders. Factors that negatively affected growth in the historic period were high associated costs and tumorigenicity risks.

Going forward, rising number of clinical trials, growth in drug discovery and development, favorable government initiatives and growth in genomic projects will drive growth. Factor that could hinder the growth of the induced pluripotent stem cell (iPSC) market in the future include were limited reimbursement coverage and lack of awareness on induced pluripotent stem cell.

Induced Pluripotent Stem Cell (iPSC) Market Drivers

The key drivers of the induced pluripotent stem cell (IPSC) market include:

Rising Number Of Clinical Trials

Rising number of clinical trials is expected to propel the growth of the induced pluripotent stem cell (iPSC) market going forward. iPSCs are increasingly used in disease modeling, toxicity screening, and regenerative therapies, leading to a surge in clinical trials—accelerating market adoption and validation. As clinical trials increase, more iPSC-based therapies are being tested for a range of conditions, enhancing their viability in regenerative and personalized medicine. Successful trials boost market confidence, encouraging both investors and healthcare providers to adopt iPSC solutions. iPSCs also improve disease models for drug discovery, reducing reliance on animal studies and accelerating the development process. These factors collectively drive the growing market for iPSC-based therapies and research tools. The rising number of clinical trials growth contribution during the forecast period in 2024 is 1.45%.

Induced Pluripotent Stem Cell (iPSC) Market Restraints

The key restraints on the induced pluripotent stem cell (IPSC) market include:

Limited Reimbursement Coverage

Limited reimbursement coverage is expected to hamper the growth of the induced pluripotent stem cell (iPSC) market. Lack of insurance coverage for stem cell-based therapies and diagnostics significantly limits patient access and commercial viability. The high cost of developing and producing iPSC-based therapies, including the expenses of generating iPSCs, maintaining cultures and performing advanced procedures, makes these treatments unaffordable for many patients without proper reimbursement coverage. Healthcare providers may be reluctant to adopt these therapies if they are not covered by insurance, slowing their market growth. Additionally, the lack of clear and consistent reimbursement policies creates uncertainty, hindering investment and delaying clinical trials, which ultimately delays the availability of iPSC-based therapies. Growth affected by limited reimbursement coverage during the forecast period in 2024 is -1.70%.

Induced Pluripotent Stem Cell (iPSC) Market Trends

Major trends shaping the induced pluripotent stem cell (IPSC) market include:

Ready-To-Use iPSC Cell Lines Pave Way For Off-The-Shelf Cell Therapies

Major companies operating in the induced pluripotent stem cell (iPSC) market are focusing on developing innovative ready-to-use, immune-cloaked iPSC cell lines to enhance the scalability and cost-effectiveness of cell therapies. These immune-cloaked cell lines are designed to evade immune rejection, facilitating their use in allogeneic therapies. By reducing the need for patient-specific cell preparation, these advancements aim to accelerate the development of off-the-shelf cell therapies for a broader range of conditions. For example, in February 2025, Cellistic, a US-based pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing services, launched Allo Chassis—ready-to-use, immune-cloaked iPSC cell lines derived from CD34+ (hematopoietic stem cells) and CD4+ (helper T-cell) primary cells. These cell lines are engineered using Cellistic’s proprietary STAR-CRISPR (CRISPR-based gene editing technology) to delete HLA class I and II antigens, minimizing immune rejection in allogeneic (donor-derived) therapies. Manufactured under current Good Manufacturing Practice (cGMP) standards, Allo Chassis offers therapeutic developers a cost-effective and time-efficient solution for creating product-specific master cell banks. The cell lines are available for immediate use and customization, streamlining the development of cell therapies for various applications, including regenerative medicine, immune-evasive CAR-T (Chimeric Antigen Receptor T-cell) and NK (Natural Killer) cell therapies, tissue engineering and organ transplantation.

Innovative iPSC-Based Cancer Therapy Moves Forward With Significant Investment

Major companies operating in the induced pluripotent stem cell (iPSC) market are strategically investing by focusing on the development of advanced cell culture systems and tools to improve iPSC generation, differentiation and characterization processes. They are actively working on optimizing production methods for higher efficiency and scalability, addressing challenges in regulatory compliance and developing new applications in drug discovery, regenerative medicine and disease modeling. For example, in August 2024, Shinobi Therapeutics, a US-based biotechnology company pioneering the development of off-the-shelf, immune-evasive cell therapies derived from induced pluripotent stem cells (iPSCs), secured a non-dilutive grant of up to $59 million from the Japanese Agency for Medical Research and Development (AMED) to advance its lead iPS-T cell therapy targeting GPC3-positive solid tumors. This funding will support the development of Shinobi's immune-evasive iPSC-derived T cell therapies, which aim to provide scalable, off-the-shelf treatments for cancer patients.

Opportunities And Recommendations In The Induced Pluripotent Stem Cell (iPSC) Market

Opportunities – The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by derived cell type will arise in the fibroblasts segment, which will gain $407.60 million of global annual sales by 2029. The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by application will arise in the drug discovery and toxicity studies segment, which will gain $450.37 million of global annual sales by 2029. The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by end-user will arise in the pharmaceutical and biotechnology companies segment, which will gain $543.74 million of global annual sales by 2029. The induced pluripotent stem cell (iPSC) market size will gain the most in the USA at $395.50 million.

Recommendations- To take advantage of the opportunities, The Business Research Company recommends the induced pluripotent stem cell (iPSC) to focus on scaling allogeneic therapies with immune-cloaked iPSC lines, focus on advancing cell culture systems to improve iPSC efficiency and application, focus on standardized GMP-compliant iPSC lines to streamline development, focus on developing iPSC-derived BBB models to support CNS drug discovery, focus on hepatocytes to maximize growth opportunities, focus on regenerative medicine to drive long-term growth, expand in emerging markets, focus on strategic partnerships to accelerate iPSC development and commercialization, focus on competitive and value-based pricing to strengthen market position, focus on targeted outreach to key decision-makers in research and therapeutics, focus on strengthening digital channels to accelerate lead conversion and focus on academic and research institutes to capture highest growth.

Book your 30 minutes free consultation with our research experts

Induced Pluripotent Stem Cell (iPSC) Market Segmentation

The induced pluripotent stem cell (IPSC) market is segmented by derived cell type, by application and by end-user.

By Derived Cell Type –

The induced pluripotent stem cell (IPSC) market is segmented by derived cell type into:

a)Hepatocytes

b)Fibroblasts

c)Keratinocytes

d)Amniotic Cells

e)Other Derived Cell Types

The fibroblasts market was the largest segment of the induced pluripotent stem cell (iPSC) market segmented by derived cell type, accounting for 33.83% or $663.66 million of the total in 2024. Going forward, the hepatocytes segment is expected to be the fastest growing segment in the induced pluripotent stem cell (iPSC) market segmented by derived cell type, at a CAGR of 10.78% during 2024-2029.

By Application –

The induced pluripotent stem cell (IPSC) market is segmented by application into:

a) Academic Research

b)Drug Discovery And Toxicity Studies

c)Regenerative Medicine

d)Cell And Gene Therapy

The drug discovery and toxicity studies market was the largest segment of the induced pluripotent stem cell (iPSC) market segmented by application, accounting for 41.04% or $805.14 million of the total in 2024. Going forward, the regenerative medicine segment is expected to be the fastest growing segment in the induced pluripotent stem cell (iPSC) market segmented by application, at a CAGR of 10.88% during 2024-2029.

By End-User –

The induced pluripotent stem cell (IPSC) market is segmented by end-user into:

a)Academic And Research Institutes

b)Pharmaceutical And Biotechnology Companies

c)Other End Users

The pharmaceutical and biotechnology companies market was the largest segment of the induced pluripotent stem cell (iPSC) market segmented by end-user, accounting for 53.43% or $1,048.12 million of the total in 2024. Going forward, the academic and research institutes segment is expected to be the fastest growing segment in the induced pluripotent stem cell (iPSC) market segmented by end-user, at a CAGR of 11.49% during 2024-2029.

By Geography - The induced pluripotent stem cell (IPSC) market is segmented by geography into:

oAsia Pacific

•China

•India

•Japan

•Australia

•Indonesia

•South Korea

oNorth America

•USA

•Canada

oSouth America

•Brazil

oWestern Europe

•France

•Germany

•UK

•Italy

•Spain

oEastern Europe

•Russia

oMiddle East

oAfrica

North America was the largest region in the induced pluripotent stem cell (iPSC) market, accounting for 41.77% or $819.41 million of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the induced pluripotent stem cell (iPSC) market will be Asia Pacific and South America where growth will be at CAGRs of 11.60% and 9.39% respectively. These will be followed by North America and Eastern Europe where the markets are expected to grow at CAGRs of 9.15% and 8.79% respectively.

Induced Pluripotent Stem Cell (iPSC) Market Competitive Landscape

Major Competitors are:

FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc)

Thermo Fisher Scientific Inc.

STEMCELL Technologies Inc.

Lonza Group AG

Miltenyi Biotec GmbH

Other Competitors Include:

Takara Bio Inc.

Astellas Pharma Inc.

Fate Therapeutics Inc.

ViaCyte Inc.

Sartorius

Cynata Therapeutics Limited

Shenzhen Bioscience

Dainippon Sumitomo Pharma

Shanghai Cell Therapy Group

Car-T Bio

JW Therapeutics

Fosun Kite Biotechnology

Shanghai UniCar Therapy

Shinobi Therapeutics

Merck Sharp & Dohme

Evolus

Merz Pharma

AbbVie

Ipsen

AusBiotech Ltd

LifeCell International

iPS Bio, Inc.

Karis Bio

Cellino Biotech

MEDIPOST Co., Ltd.

Qilu Pharmaceutical Co., Ltd

Japan Tissue Engineering Co., Ltd

Nuwacell Biotechnologies Co., Ltd.

Shanghai IxCell Biotech Co., Ltd.

iRegene Therapeutics

CellSeed, Inc.

Celltrion

Galderma SA

HUGEL, Inc

Croma-Pharma GmbH

Fastox Pharma SA

Avectas

Albumedix Ltd

Kite Pharma

Gilead Sciences

Renuron Group

Smart Cells

Genenta Science

CellGenix

Cellcolabs AB

Axol Bioscience

RigeneranD S.r.l.

SEED Biosciences SA

Selvita

Mabion S.A.

Roche Holding AG

Resolution Therapeutics

Ncardia BV

Evotec A.G.

Alzheon

Zentiva Group, a.s.

Bochemie a.s.

Tolion Health

Sinclair Pharma

Pfizer

Pharmasyntez

Mabion

Pure Biologics

Proteon Pharmaceuticals

GlaxoSmithKline

Parexel

Bayer

Synbio Technologies

OmniaBio

Medipost Co

QHP Capital

Applied StemCell

Century Therapeutics

Bristol Myers Squibb

StemCyte, Inc.

Vertex Pharmaceuticals Incorporated

Fate Therapeutics

ThermoGenesis Holdings

BioCanRx

CellCAN

CCRM

C3i

Gameto

BioCells

Banco de Cordon del Peru

CryoHoldco

Rege Nephro

CellSave Arabia

Life Cell

AmiCare

Cells4life

ReeLabs

Royan Stem Cell Technology Co.

Next BioSciences

CryoSave

BioHeart

Net Cells

Cell Safe Bank

StemPlus

Author: Abdul Wasay

Induced Pluripotent Stem Cell (iPSC) Market Size

The global induced pluripotent stem cell (iPSC) market reached a value of nearly $2,686.3 million in 2022, having increased at a compound annual growth rate (CAGR) of 10.7% since 2017. The market is expected to grow from $2,686.3 million in 2022 to $4,363.7 million in 2027 at a rate of 10.2%. The market is then expected to grow at a CAGR of 9.2% from 2027 and reach $6,763.4 million in 2032.

Growth in the historic period resulted from increasing healthcare expenditure, a rise in funding, rising awareness of stem cell products' medicinal potential, use of induced pluripotent stem cell (iPSC) based drug discovery, increasing demand for personalized medicine and cost-effective benefits of iPSC for drug discovery. Factors that negatively affected growth in the historic period were a lack of awareness on induced pluripotent stem cell, high associated costs, technical limitations and lengthy process and inadequate reimbursements.

Going forward, an increasing prevalence of chronic diseases, growth in genomic projects, development of iPSC-derived disease models, an increasing prevalence of genetic diseases, government initiatives and a rapid increase in technology will drive the market. Factors that could hinder the growth of the induced pluripotent stem cell (iPSC) market in the future include automation of iPSC production, the risk associated with induced pluripotent stem cell treatment, disruption of medical facilities due to the Russia-Ukraine war and the coronavirus pandemic and high storage cost.

Induced Pluripotent Stem Cell (iPSC) Market Drivers

The key drivers of the induced pluripotent stem cell (iPSC) market include:

Increasing Prevalence Of Chronic Diseases

During the forecast period, the increasing prevalence of chronic diseases will support the growth of the induced pluripotent stem cell market. Chronic disorders such as diabetes, cancer, cancer, and stroke can be treated with induced pluripotent stem cells. Any tissue from a child or adult can be utilized to generate induced pluripotent stem cells, which have been genetically modified to behave like embryonic stem cells. For instance, in December 2022, according to Centers for Disease Control and Prevention, a US-based government agency, estimates that 6 out 10 adults in US have a chronic disease. Additionally, in January 2023, according to American Cancer Society (ACS) estimates, there will be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States in 2023. Therefore, rise in incidences of chronic diseases is expected to drive the demand for induced pluripotent stem cell treatment in the forecast period.

Induced Pluripotent Stem Cell (iPSC) Market Restraints

The key restraints on the induced pluripotent stem cell (iPSC) market include:

Automation Of iPSC Production

Automation in the production of induced pluripotent stem cells (iPSC) is expected to inhibit the growth of the market. There is a deficiency in industrial processes for large scale production of human iPS cells for drug development. One reason is the high complexity of the manual processes involved and the need for highly qualified and experienced laboratory staff. Established biotechnological methods aim for a large scale production of one specific cell type. The iPS cell technology however demands the production, generation and differentiation of large numbers of individual iPS cell clones with the respective quality control. The transfer of manual laboratory processes for reprogramming, selection and expansion to an automatic production process requires innovative solutions when it comes to the system control unit. A major challenge is the systematic parallelization of all biotechnological production steps. Therefore, the adaptation of iPS cell production to industrial formats and automatic process steps for high throughput screening (HTS) has remained a major challenge, limiting market growth.

Induced Pluripotent Stem Cell (iPSC) Market Trends

Major trends influencing the induced pluripotent stem cell (iPSC) market include:

Development of Pluripotent Stem Cells For Parkinson’s Disease (PD)

Development of pluripotent stem cells for the treatment of Parkinson’s Disease (PD) is a key therapeutic objective in the induced pluripotent stem cell (iPSC) market. iPSCs can be used to generate dopaminergic neurons for transplantation or to model PD in the lab. Extensive research is being conducted on the use of induced pluripotent stem cells to treat Parkinson’s disease (PD). For instance, in April 2022, Aspen Neuroscience Inc., a US-based biotechnology company, launched first patient screening study for planned clinical trial of personalized cell replacement in Parkinson's disease. Further, in June 2022, BlueRock Therapeutics, a Germany-based, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, established expansion of the development of cell treatments in BlueRock's pipeline, with an initial focus on the ongoing BRT-DA01 clinical trial in Parkinson's disease. The creation of a BlueRock site in Berlin enhances the company's footprint and strengthens Bayer's cell therapy capabilities.

Strategic Collaborations And Partnerships

The trend of partnerships and collaborations is expected to continue, as companies look for new ways to create value and achieve growth. This trend is becoming increasingly popular, as companies seek to adapt to a rapidly changing business environment and stay competitive. The main objective of these partnerships is to combine resources, knowledge and expertise to achieve a mutual benefit, such as gaining access to new markets, technologies or customers, cost savings or risk reduction. Major companies operating in the induced pluripotent stem cell (iPSC) market are undertaking strategic initiatives such as collaborations and partnerships for product innovation to sustain in the increasingly competitive market. For instance, in November 2020, FUJIFILM Cellular Dynamics, Inc., a US-based developer and manufacturer of human-induced pluripotent stem cells (iPSCs) partnered with Lonza Walkersville, Inc., a US-based GMP iPSC manufacturer. Through this partnership, FUJIFILM Cellular Dynamics grants Lonza a non-exclusive licence to use its iPSC generation patents, and Lonza grants FUJIFILM Cellular Dynamics expanded use of its innovative Nucleofector technology. Through licencing agreements, the two companies combine their resources to create human induced pluripotent stem cells. Further, in September 2021, Bone Therapeutics, a Belgium-based bone cell therapy company, partnered with Implant Therapeutics, a US-based biotech company that engineers hypoimmunogenic iPSC-MSC cells containing panCELLa’s FailSafe and iACT Stealth Cell technologies. The collaboration will make Implant Therapeutics induced pluripotent stem cell (iPSC) lines, medium, differentiation techniques, and expertise available to Bone Therapeutics for access, evaluation, and material transfer.

Opportunities And Recommendations In The Induced Pluripotent Stem Cell (iPSC) Market

Opportunities –The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by derived cell type will arise in the fibroblasts market, which will gain $495.1 million of global annual sales by 2027. The top growth potential in the induced pluripotent stem cell (iPSC) market by application will arise in the drug discovery and toxicity studies market, which will gain $761.9 million of global annual sales by 2027. The top growth potential in the induced pluripotent stem cell (iPSC) market by end-users will arise in research laboratories market, which will gain $1,085.4 million of global annual sales by 2027. The induced pluripotent stem cell (iPSC) market size will gain the most in the USA at $267.8 million.

Recommendations-To take advantage of the opportunities, The Business Research Company recommends the induced pluripotent stem cell (iPSC) companies to focus on development of pluripotent stem cells for Parkinson’s disease (PD), focus on induced pluripotent stem cell iPSC-derived natural killer (NK) cells, focus on cell therapy, focus on iPSC expansion medium, focus on personalized iPSC, focus on pluripotent stem cells for type 1 diabetes, expand in emerging markets, continue to focus on developed markets, focus on partnerships and collaborations, provide competitively priced offerings, participate in trade shows and events, continue to use B2B promotions, target fast-growing end-users, continue to target fast-growing applications and target the elderly population.

Induced Pluripotent Stem Cell (iPSC) Market Segmentation

The induced pluripotent stem cell (iPSC) market is segmented by derived cell type, by application and by end-user.
By Derived Cell Type -
The induced pluripotent stem cell (iPSC) market is segmented by derived cell type into:

a) Hepatocytes
b) Fibroblasts
c) Keratinocytes
d) Amniotic Cells
e) Other Derived Cell Types

The fibroblasts was the largest segment of the induced pluripotent stem cell (iPSC) market by derived cell type, accounting for $792.7 million or 29.5% of the total market in 2022. The other derived cell types market is expected to be the fastest-growing segment going forward at a CAGR of 10.7%.
By Application-
The induced pluripotent stem cell (iPSC) market is segmented by application into:

a) Academic Research
b) Drug Discovery And Toxicity Studies
c) Regenerative Medicine
d) Cell And Gene Therapy

The drug discovery and toxicity studies market was the largest segment of the induced pluripotent stem cell (iPSC) market by application, accounting for $1,294.8 million or 48.2% of the total market in 2022. The cell and gene therapy market is expected to be the fastest-growing segment going forward at a CAGR of 11.7%.
By End-User –
The induced pluripotent stem cell (iPSC) market is segmented by end-user into:

a) Hospitals
b) Research Laboratories

The research laboratories was the largest segment of the induced pluripotent stem cell (iPSC) market by end-users, accounting for $1,826.3 million or 86.0% of the total market in 2022. The hospitals market is expected to be the fastest-growing segment going forward at a CAGR of 11.0%.
By Geography - The induced pluripotent stem cell (iPSC) market is segmented by geography into:

• China
• India
• Japan
• Australia
• Indonesia
• South Korea

• USA

• Brazil

• France
• Germany
• UK

• Russia

North America was the largest region in the induced pluripotent stem cell (iPSC) market, accounting for 47.7% of the global market in 2022. It was followed by Western Europe, Asia Pacific and the other regions. Going forward, the fastest growing regions in the induced pluripotent stem cell (iPSC) market will be South America and Middle East, where growth will be at CAGRs of 31.3% and 29.6%respectively from 2022-2027.

Induced Pluripotent Stem Cell (iPSC) Market Competitive Landscape

Major Competitors are:

FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc)

Thermo Fisher Scientific, Inc

Takara Bio, Inc

Lonza Group AG

Astellas Pharma Inc

Other Competitors Include:

ViaCyte, Inc

Ncardia

REPROCELL USA, Inc

Japan Tissue Engineering Co., Ltd

Merck KGaA

Cynata Therapeutics Limited

Dainippon Sumitomo Pharma

Shenzhen Bioscience

Shanghai Cell Therapy Group

Car-T Bio

JW therapeutics

Fosun Kite Biotechnology

Shanghai UniCar Therapy

Takaria Bio

REPROCELL

SEED Biosciences SA

Cellerix

CellGenix

NsGene

TiGenix

Renuron Group

Smart Cells

Genenta Science

Biocad Rf

MSD

Pfizer

Roche

Pharmasyntez

Selvita

Mabion

Pure Biologics

OncoArendi Therapeutics

Proteon Pharmaceuticals

GlaxoSmithKline

Parexel

Bayer

Thermo Fisher Scientific

Fate Therapeutics

ViaCyteSangamo Therapeutics

Athersys

BrainStorm Cell Therapeutics

Cellular Biomedicine Group

Pluristem Therapeutics

Gamida Cell

VistaGen Therapeutics

Caladrius Biosciences

ThermoGenesis Holdings

BioCanRx

CellCAN

CCRM

C3i

BioCells Argentina

Banco de Cordon del Peru

CryoHoldco

CellSave Arabia

Life Cell

AmiCare

Cells4life

ReeLabs

Stem Cells

Royan Stem Cell Technology Co.

Next BioSciences

CryoSave

BioHeart

Stem Cell Technologies

Net Cells

1Executive Summary

1.1Induced Pluripotent Stem Cell (iPSC) – Market Attractiveness And Macro Economic Landscape

2Table Of Contents

3List Of Tables

4List Of Figures

5Report Structure

6Market Characteristics

6.1General Market Definition

6.2Summary

6.3Induced Pluripotent Stem Cell (iPSC) Market Definition And Segmentations

6.4Market Segmentation By Derived Cell Type

6.4.1Hepatocytes

6.4.2Fibroblasts

6.4.3Keratinocytes

6.4.4Amniotic Cells

6.4.5Other Derived Cell Types

6.5Market Segmentation By Application

6.5.1Academic Research

6.5.2Drug Discovery And Toxicity Studies

6.5.3Regenerative Medicine

6.5.4Cell And Gene Therapy

6.6Market Segmentation By End-User

6.6.1Academic And Research Institutes

6.6.2Pharmaceutical And Biotechnology Companies

6.6.3Other End Users

7Major Market Trends

7.1Ready-To-Use iPSC Cell Lines Pave Way For Off-The-Shelf Cell Therapies

7.2Innovative iPSC-Based Cancer Therapy Moves Forward With Significant Investment

7.3Standardized iPSC Lines Enhance Efficiency In Therapeutic Development

7.4Strategic Partnership Targets Commercialization Of Gene-Edited iPSCs

7.5Advancing CNS Drug Development With Human iPSC-Based BBB Models

8Global Induced Pluripotent Stem Cell (iPSC) Growth Analysis And Strategic Analysis Framework

8.1Global: PESTEL Analysis

8.1.1Political

8.1.2Economic

8.1.3Social

8.1.4Technological

8.1.5Environmental

8.1.6Legal

8.2Analysis Of End Use Industries (B2B)

8.2.1Pharmaceutical And Biotechnology Companies

8.2.2Academic And Research Institutes

8.2.3Other End Users

8.3Global Induced Pluripotent Stem Cell (iPSC) Market Growth Rate Analysis

8.4Historic Market Growth, 2019 – 2024, Value ($ Million)

8.4.1Market Drivers 2019 – 2024

8.4.2Market Restraints 2019 – 2024

8.5Forecast Market Growth, 2024 – 2029, 2034F Value ($ Million)

8.6Forecast Growth Contributors/Factors

8.6.1Quantitative Growth Contributors

8.6.2Drivers

8.6.3Restraints

8.7Global Induced Pluripotent Stem Cell (iPSC) Total Addressable Market (TAM)

9Global Induced Pluripotent Stem Cell (iPSC) Market Segmentation

9.1Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

9.2Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

9.3Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

9.4Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Hepatocytes, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

9.5Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Fibroblasts, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

9.6Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Keratinocytes, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

9.7Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation By Amniotic Cells, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

9.8Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation By Other Derived Cells, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

10Induced Pluripotent Stem Cell (iPSC) Market, Regional and Country Analysis

10.1Global Induced Pluripotent Stem Cell (iPSC) Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

10.2Global Induced Pluripotent Stem Cell (iPSC) Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11Asia-Pacific Market

11.1Summary

11.2Market Overview

11.2.1Region Information

11.2.2Market Information

11.2.3Background Information

11.2.4Government Initiatives

11.2.5Regulations

11.2.6Regulatory Bodies

11.2.7Major Associations

11.2.8Taxes Levied

11.2.9Corporate Tax Structure

11.2.10Investments

11.2.11Major Companies

11.3Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.4Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.5Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.6Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market: Country Analysis

11.7China Market

11.8Summary

11.9Market Overview

11.9.1Country Information

11.9.2Market Information

11.9.3Background Information

11.9.4Government Initiatives

11.9.5Regulations

11.9.6Regulatory Bodies

11.9.7Major Associations

11.9.8Taxes Levied

11.9.9Corporate Tax Structure

11.9.10Investments

11.9.11Major Companies

11.10China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.11China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.12China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.13India Market

11.14India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.15India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.16India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.17Japan Market

11.18Summary

11.19Market Overview

11.19.1Country Information

11.19.2Market Information

11.19.3Background Information

11.19.4Government Initiatives

11.19.5Regulations

11.19.6Regulatory Bodies

11.19.7Major Associations

11.19.8Taxes Levied

11.19.9Corporate Tax Structure

11.19.10Investments

11.19.11Major Companies

11.20Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.21Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.22Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.23South Korea Market

11.24Summary

11.25Market Overview

11.25.1Country Information

11.25.2Market Information

11.25.3Background Information

11.25.4Government Initiatives

11.25.5Regulations

11.25.6Regulatory Bodies

11.25.7Major Associations

11.25.8Taxes Levied

11.25.9Corporate Tax Structure

11.25.10Investments

11.25.11Major Companies

11.26South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.27South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.28South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.29Australia Market

11.30Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.31Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.32Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.33Indonesia Market

11.34Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.35Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

11.36Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12Western Europe Market

12.1Summary

12.2Market Overview

12.2.1Region Information

12.2.2Market Information

12.2.3Background Information

12.2.4Government Initiatives

12.2.5Regulations

12.2.6Regulatory Bodies

12.2.7Major Associations

12.2.8Taxes Levied

12.2.9Corporate tax structure

12.2.10Investments

12.2.11Major Companies

12.3Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.4Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.5Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.6Western Europe Induced Pluripotent Stem Cell (iPSC) Market: Country Analysis

12.7UK Market

12.8UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.9UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.10UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.11Germany Market

12.12Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.13Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.14Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.15France Market

12.16France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.17France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.18France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.19Italy Market

12.20Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.21Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.22Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.23Spain Market

12.24Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.25Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

12.26Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

13Eastern Europe Market

13.1Summary

13.2Market Overview

13.2.1Region Information

13.2.2Market Information

13.2.3Background Information

13.2.4Government Initiatives

13.2.5Regulations

13.2.6Regulatory Bodies

13.2.7Major Associations

13.2.8Taxes Levied

13.2.9Corporate Tax Structure

13.2.10Investments

13.2.11Major Companies

13.3Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

13.4Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

13.5Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

13.6Russia Market

13.7Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

13.8Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

13.9Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14North America Market

14.1Summary

14.2Market Overview

14.2.1Region Information

14.2.2Market Information

14.2.3Background Information

14.2.4Government Initiatives

14.2.5Regulations

14.2.6Regulatory Bodies

14.2.7Major Associations

14.2.8Taxes Levied

14.2.9Corporate Tax Structure

14.2.10Investments

14.2.11Major Companies

14.3North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.4North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.5North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.6USA Market

14.7Summary

14.8Market Overview

14.8.1Country Information

14.8.2Market Information

14.8.3Background Information

14.8.4Government Initiatives

14.8.5Regulations

14.8.6Regulatory Bodies

14.8.7Major Associations

14.8.8Taxes Levied

14.8.9Corporate Tax Structure

14.8.10Investments

14.8.11Major Companies

14.9USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.10USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.11USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.12Canada Market

14.13Summary

14.14Market Overview

14.14.1Country Information

14.14.2Market Information

14.14.3Background Information

14.14.4Government Initiatives

14.14.5Regulations

14.14.6Regulatory Bodies

14.14.7Major Associations

14.14.8Taxes Levied

14.14.9Corporate Tax Structure

14.14.10Investments

14.14.11Major Companies

14.15Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.16Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

14.17Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

15South America Market

15.1Summary

15.2Market Overview

15.2.1Region Information

15.2.2Market Information

15.2.3Background Information

15.2.4Government Initiatives

15.2.5Regulations

15.2.6Regulatory Bodies

15.2.7Major Associations

15.2.8Taxes Levied

15.2.9Corporate Tax Structure

15.2.10Investments

15.2.11Major Companies

15.3South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

15.4South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

15.5South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

15.6Brazil Market

15.7Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

15.8Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

15.9Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

16Middle East Market

16.1Summary

16.2Market Overview

16.2.1Region Information

16.2.2Market Information

16.2.3Background Information

16.2.4Government Initiatives

16.2.5Regulations

16.2.6Regulatory Bodies

16.2.7Major Associations

16.2.8Taxes Levied

16.2.9Corporate Tax Structure

16.2.10Investments

16.2.11Major Companies

16.3Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

16.4Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

16.5Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

17Africa Market

17.1Summary

17.2Market Overview

17.2.1Region Information

17.2.2Market Information

17.2.3Background Information

17.2.4Government Initiatives

17.2.5Regulations

17.2.6Regulatory Bodies

17.2.7Major Associations

17.2.8Taxes Levied

17.2.9Corporate Tax Structure

17.2.10Major Companies

17.3Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

17.4Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

17.5Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

18Competitive Landscape And Company Profiles

18.1Company Profiles

18.2FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc).

18.2.1Company Overview

18.2.2Products And Services

18.2.3Business Strategy

18.2.4Financial Overview

18.3Thermo Fisher Scientific Inc.

18.3.1Company Overview

18.3.2Products And Services

18.3.3Business Strategy

18.3.4Financial Overview

18.4STEMCELL Technologies Inc.

18.4.1Company Overview

18.4.2Products And Services

18.4.3Business Strategy

18.4.4Financial Overview

18.5Lonza Group AG

18.5.1Company Overview

18.5.2Products And Services

18.5.3Financial Overview

18.6Miltenyi Biotec GmbH

18.6.1Company Overview

18.6.2Products And Services

18.6.3Financial Overview

19Other Major Companies

19.1Takara Bio Inc.

19.1.1Company Overview

19.1.2Products And Services

19.2Astellas Pharma Inc.

19.2.1Company Overview

19.2.2Products And Services

19.3Fate Therapeutics Inc.

19.3.1Company Overview

19.3.2Products And Services

19.4ViaCyte Inc.

19.4.1Company Overview

19.4.2Products And Services

19.5Sartorius

19.5.1Company Overview

19.5.2Products And Services

19.6Shanghai Cell Therapy Group Ltd.

19.6.1Company Overview

19.6.2Products And Services

19.7Ncardia

19.7.1Company Overview

19.7.2Products And Services

19.8REPROCELL USA Inc.

19.8.1Company Overview

19.8.2Products And Services

19.9Applied StemCells Inc.

19.9.1Company Overview

19.9.2Products And Services

19.10Treefrog Therapeutics Inc.

19.10.1Company Overview

19.10.2Products And Services

19.11Japan Tissue Engineering Co. Ltd.

19.11.1Company Overview

19.11.2Products And Services

19.12DefiniGEN

19.12.1Company Overview

19.12.2Products And Services

19.13Merck KGaA.

19.13.1Company Overview

19.13.2Products And Services

19.14iXCells Biotechnologies Inc.

19.14.1Company Overview

19.14.2Products And Services

19.15Cynata Therapeutics Limited

19.15.1Company Overview

19.15.2Products And Services

20Competitive Benchmarking

21Competitive Dashboard

22Key Mergers And Acquisitions

22.1Shineco Acquired InfiniClone Ltd

22.2Axol Bioscience Ltd Acquired Phenocell SAS

22.3Century Therapeutics Acquired Clade Therapeutics

22.4QHP Capital Acquired Applied StemCell

22.5Vertex Pharmaceuticals Acquired ViaCyte

22.6Medipost Acquired OmniaBio

23Recent Developments In The Induced Pluripotent Stem Cell (iPSC) Market

23.1Revolutionary Stem Cell Banking Brings Personalized Regenerative Care To The Masses

23.2Next-Generation NK Cell Therapy Platform Enhances Clinical Readiness

23.3Revolutionizing Cardiovascular Care With Personalized iPSC Solutions

23.4AI-Powered iPSC Foundry Improving Outcomes For Parkinson’s Patients

24Opportunities And Strategies

24.1Global Induced Pluripotent Stem Cell (iPSC) Market In 2029 – Countries Offering Most New Opportunities

24.2Global Induced Pluripotent Stem Cell (iPSC) Market In 2029 – Segments Offering Most New Opportunities

24.3Global Induced Pluripotent Stem Cell (iPSC) Market In 2029 – Growth Strategies

24.3.1Market Trend Based Strategies

24.3.2Competitor Strategies

25Induced Pluripotent Stem Cell (iPSC) Market, Conclusions And Recommendations

25.1Conclusions

25.2Recommendations

25.2.1Product

25.2.2Place

25.2.3Price

25.2.4Promotion

25.2.5People

26Appendix

26.1Geographies Covered

26.2Market Data Sources

26.3Research Methodology

26.4Currencies

26.5The Business Research Company

26.6Copyright and Disclaimer

List Of Tables

Table 1: Global Induced Pluripotent Stem Cell (iPSC) Market, Historic, 2019 – 2024, $ Million

Table 2: Global Induced Pluripotent Stem Cell (iPSC) Market, Forecast, 2024 – 2029, 2034F, $ Million

Table 3: Global Induced Pluripotent Stem Cell (iPSC) Market TAM, 2024 And 2034, $ Million

Table 4: Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 5: Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 6: Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 7: Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Hepatocytes, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 8: Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Fibroblasts, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 9: Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Keratinocytes, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 10: Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation By Amniotic Cells, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 11: Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation By Other Derived Cells, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 12: Global Induced Pluripotent Stem Cell (iPSC) Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 13: Global Induced Pluripotent Stem Cell (iPSC) Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 14: Asia-Pacific GDP Per Capita, By Country, 2019-2024, $

Table 15: Asia-Pacific Population, By Country, 2019-2029, Millions

Table 16: Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 17: Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 18: Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 19: China GDP Per Capita, 2019-2024, $

Table 20: China Population, 2019-2029, Millions

Table 21: China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 22: China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 23: China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 24: India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 25: India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 26: India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 27: Japan GDP Per Capita, 2019-2024, $

Table 28: Japan Population, By Country, 2019-2029, Millions

Table 29: Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 30: Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 31: Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 32: South Korea GDP Per Capita, 2019-2024, $

Table 33: South Korea Population, 2019-2029, Millions

Table 34: South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 35: South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 36: South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 37: Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 38: Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 39: Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 40: Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 41: Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 42: Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 43: Western Europe GDP Per Capita, By Country, 2019-2024, $

Table 44: Western Europe Population, By Country, 2019-2029, Millions

Table 45: Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 46: Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 47: Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 48: UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 49: UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 50: UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 51: Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 52: Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 53: Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 54: France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 55: France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 56: France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 57: Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 58: Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 59: Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 60: Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 61: Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 62: Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 63: Eastern Europe GDP Per Capita, By Country, 2019-2024, $

Table 64: Eastern Europe Population, By Country, 2019-2029, Millions

Table 65: Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 66: Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 67: Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 68: Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 69: Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 70: Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 71: North America GDP Per Capita, By Country, 2019-2024, $

Table 72: North America Population, By Country, 2019-2029, Millions

Table 73: North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 74: North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 75: North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 76: USA GDP Per Capita, 2019-2024, $

Table 77: USA Population, 2019-2029, Millions

Table 78: USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 79: USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 80: USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 81: Canada GDP Per Capita, 2019-2024, $

Table 82: Canada Population, By Country, 2019-2029, Millions

Table 83: Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 84: Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 85: Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 86: South America GDP Per Capita, By Country, 2019-2024, $

Table 87: South America Population, By Country, 2019-2029, Millions

Table 88: South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 89: South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 90: South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 91: Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 92: Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 93: Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 94: Middle East GDP Per Capita, By Country, 2019-2024, $

Table 95: Middle East Population, By Country, 2019-2029, Millions

Table 96: Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 97: Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 98: Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 99: Africa GDP Per Capita, By Country, 2019-2024, $

Table 100: Africa Population, By Country, 2019-2029, Millions

Table 101: Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 102: Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 103: Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Table 104: Global Induced Pluripotent Stem Cell (iPSC) Market, Key Competitor Estimated Market Shares, 2023, Percentage (%)

Table 105: FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc)– Financial Overview, 2019 – 2023, $ Billion

Table 106: Thermo Fisher Scientific Inc– Financial Overview, 2019 – 2023, $ Billion

Table 107: STEMCELL Technologies Inc– Financial Overview, 2023, $Billion

Table 108: Lonza Group AG– Financial Overview, 2019 – 2023, $Billion

Table 109: Miltenyi Biotec GmbH – Financial Overview, 2023, $Billion

Table 110: Induced Pluripotent Stem Cell (iPSC) Market, Competitive Benchmarking (In USD Millions)

Table 111: Induced Pluripotent Stem Cell (iPSC) Market, Competitive Dashboard

Table 112: Global Induced Pluripotent Stem Cell (iPSC) Market Size Gain ($ Million), 2024 – 2029, By Country

Table 113: Global Induced Pluripotent Stem Cell (iPSC) Market Size Gain ($ Million), Segmentation By Derived Cell Type, 2024 – 2029

Table 114: Global Induced Pluripotent Stem Cell (iPSC) Market Size Gain ($ Million), Segmentation By Application, 2024 – 2029

Table 115: Global Induced Pluripotent Stem Cell (iPSC) Market Size Gain ($ Million), Segmentation By End-User, 2024 – 2029

Table 116: Induced Pluripotent Stem Cell (iPSC) Market Data Sources

List Of Figures

Figure 1: Global Induced Pluripotent Stem Cell (IPSC) Market Segmentation By Derived Cell Type

Figure 2: Global Induced Pluripotent Stem Cell (IPSC) Market Segmentation By Application

Figure 3: Global Induced Pluripotent Stem Cell (IPSC) Market Segmentation By End-User

Figure 4: Global Induced Pluripotent Stem Cell (iPSC) Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 5: Global Induced Pluripotent Stem Cell (iPSC) Market, Historic, 2019 – 2024, $ Million

Figure 6: Global Induced Pluripotent Stem Cell (iPSC) Market, Forecast, 2024 – 2029, 2034F, $ Million

Figure 7: Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 8: Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 9: Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 10: Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Hepatocytes, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 11: Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Fibroblasts, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 12: Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation Of Keratinocytes, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 13: Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation By Amniotic Cells, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 14: Global Induced Pluripotent Stem Cell (iPSC) Market, Sub-Segmentation By Other Derived Cells, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 15: Global Induced Pluripotent Stem Cell (iPSC) Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 16: Global Induced Pluripotent Stem Cell (iPSC) Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 17: Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 18: Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 19: Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 20: China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 21: China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 22: China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 23: India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 24: India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 25: India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 26: Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 27: Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 28: Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 29: South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 30: South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 31: South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 32: Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 33: Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 34: Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 35: Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 36: Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 37: Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 38: Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 39: Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 40: Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 41: UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 42: UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 43: UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 44: Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 45: Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 46: Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 47: France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 48: France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 49: France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 50: Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 51: Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 52: Italy Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 53: Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 54: Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 55: Spain Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 56: Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 57: Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 58: Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 59: Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 60: Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 61: Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 62: North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 63: North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 64: North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 65: USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 66: USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 67: USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 68: Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 69: Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 70: Canada Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 71: South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 72: South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 73: South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 74: Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 75: Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 76: Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 77: Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 78: Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 79: Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 80: Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 81: Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 82: Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million

Figure 83: Global Induced Pluripotent Stem Cell (iPSC) Market, Key Competitor Estimated Market Shares, 2023, Percentage (%)

Figure 84: FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc)– Financial Overview, 2019 – 2023, $ Billion

Figure 85: Thermo Fisher Scientific Inc– Financial Overview, 2019 – 2023, $ Billion

Figure 86: Lonza Group AG. – Financial Overview, 2019 – 2023, $ Billion

Figure 87: Geographic Regions Covered